Cancer Control With Radical Prostatectomy Alone in 1,000 Consecutive Patients

Hull, Gerald W.; Rabbani, Farhang; Abbas, Farhat; Wheeler, Thomas M.; Kattan, Michael W.; Scardino, Peter T.

doi:10.1097/00005392-200202000-00018

Cited by 373 publications

(426 citation statements)

References 21 publications

Supporting

Mentioning

363

Contrasting

Unclassified

Order By: Relevance

“…A greater portion of patients with high-grade disease may have affected the outcomes in this study. When stratified by pathologic stage or Gleason score, the biochemical outcomes of our series seemed similar with the results of previous RARP [11][12][13] or open [28][29][30] series. Regarding the relatively high incidence of positive surgical margin in this study, this may be partly associated with immature surgical techniques as initial cases of RARP were included in this study.…”

Section: Discussionsupporting

confidence: 85%

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Kim¹,

Lim²,

Shin³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

In this study, we assessed biochemical outcomes after robot-assisted radical prostatectomy (RARP). Between July 2005 and November 2007, one hundred and seventy-six consecutive patients treated by RARP without neoadjuvant treatment were included in this study. All procedures were performed by a single surgeon and the median follow-up period was 60 months (interquartile range (IQR): 59-69). The median prostate specific antigen was 7.50 ng ml 21 (IQR: 5.14-11.45) and 39.2% of the patients were classified as intermediate risk and 15.3% were classified as high risk; on final pathological examination, 35.2% of the patients had non-organ confined disease and 37.5% and 14.2% had Gleason scores of 7 and 8-10, respectively. The biochemical recurrence (BCR)-free survival rates at 3 and 5 years were 85.6% and 81.2%, respectively. The 5-year BCR-free survival rates stratified by pathologic Gleason scores were 93.1% in Gleason scores of 6 or less, 74.5% in a Gleason score of 7, and 58.1% in Gleason scores of 8 or greater, respectively (P,0.001). When stratified by pathologic stage, the BCR-free survival rates were 89.8% in pT2 patients, 66.2% in pT3a patients, and 39.3% in pT3b patients at 5 years following RARP, respectively (P,0.001). Preoperative prostate-specific antigen (PSA), pathologic stage, postoperative Gleason score and surgical margin status were independently associated with BCR in multivariate analysis. In this study, we report biochemical outcomes after RARP with the longest follow-up periods to date in Asian men. We found that robotic surgery provided satisfactory biochemical outcomes, and that RARP is a safe and effective procedure in terms of oncologic outcomes.

show abstract

Section: Discussionsupporting

confidence: 85%

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Kim¹,

Lim²,

Shin³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…These results differ markedly from Western reports because of the widespread use of PSA-based screening programs in the United States and Europe. In the United States and Europe, PC is usually asymptomatic at diagnosis, the DRE is normal and PC is diagnosed on the sole basis of increased PSA in > 60% of cases [7]. Obviously, detection of organconfined PC would dramatically improve patient outcome [4].…”

Section: Introductionmentioning

confidence: 99%

Age-specific PSA reference ranges in Chinese men without prostate cancer

Liu¹,

Sun²,

Xu³

et al. 2008

Asian J Androl

View full text Add to dashboard Cite

This study is to determine age-specific prostate-specific antigen (PSA) distributions in Chinese men without prostate cancer (PC) and to recommend reference ranges for this population after comparison with other studies. From September 2003 to December 2006, 9 374 adult men aged from 18 to 96 years agreed to participate in the study. After all cases of PC were excluded, 8 422 adult men participated in statistical analysis and were divided into five age groups. Simple descriptive statistical analyses were carried out and quartiles and 95th percentiles were calculated for each age group. The age-specific PSA reference ranges are as follows: 40-49 years, 2.15 ng mL -1 ; 50-59 years, 3.20 ng mL -1 ; 60-69 years, 4.10 ng mL -1 ; 70-79 years, 5.37 ng mL -1 . The results indicate that the ethnic differences in PSA levels are obvious. The currently adopted Oesterling's age-specific PSA reference ranges are not appropriate for Chinese men. The reference ranges of this study should be more suitable to Chinese men.

show abstract

“…At 10 years of follow-up, the progression-free survival rate of organ-confined prostate cancer (pT2) is 92%, whereas for locally advanced cancer (pT3%) it is 53%. 2 It is very difficult to predict which patients with rising PSA levels (biochemical failure (BF)) will progress rapidly to advanced disease. A better prognostic factor is needed to help clinicians determine the most appropriate therapies.…”

Section: Introductionmentioning

confidence: 99%

Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization

Fukasawa

Kino

Kobayashi

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Prostate-specific antigen (PSA) screening has led to a remarkable increase in prostate cancer cases undergoing operative therapy. Over half of patients with locally advanced cancer (^pT3) develop rising PSA levels (biochemical failure) within 10 years. It is very difficult to predict which patients will progress rapidly to advanced disease following biochemical failure (BF). Therefore, a more useful prognostic factor is needed to suggest the most appropriate therapies for each patient. To determine chromosomal aberrations, we examined 30 patients with stage pT2 or pT3 primary prostate adenocarcinomas and no metastases (pN0M0) by comparative genomic hybridization (CGH). Laser capture microdissection (LCM) was used to gather cancer cells from frozen prostate specimens. Common chromosomal alterations included losses on 2q23-24, 4q26-28, 6q14-22, 8p12-22 and 13q21-31, as well as gains on 1p32-36, 6p21 and 17q21-22. Losses at 8p12-22 and 13q21-31 were observed more frequently in pT3 than pT2 tumors (Po0.05 and Po0.01, respectively). Losses at 8p12-22 were more frequent in tumors with BF (Po0.05), and those at 13q12-21 were more frequent in tumors with Gleason score (GS) 7 or more than lower GS (Po0.05). These findings suggest that losses of 8p12-22 and 13q21-31 are important determinants of prostate cancer progression.

show abstract

Cancer Control With Radical Prostatectomy Alone in 1,000 Consecutive Patients

Cited by 373 publications

References 21 publications

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years

Age-specific PSA reference ranges in Chinese men without prostate cancer

Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization

Contact Info

Product

Resources

About